Orlistat
- Generic Name
- Orlistat
- Brand Names
- Alli, Xenical, Alli (previously Orlistat GSK)
- Drug Type
- Small Molecule
- Chemical Formula
- C29H53NO5
- CAS Number
- 96829-58-2
- Unique Ingredient Identifier
- 95M8R751W8
- Background
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.
...
- Indication
Orlistat is indicated for obesity management including weight loss and weight maintenance when used in combination with calorie reduction in overweight and obese adults; this indication applies to both the prescription formulation of 120 mg and the over-the-counter formulation of 60 mg. Orlistat in the 120 mg prescription formulation is also indicated to red...
- Associated Conditions
- Weight Gain
- Associated Therapies
- Weight Reduction
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
- Conditions
- Interventions
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 136
- Registration Number
- NCT01351753
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 174
- Registration Number
- NCT01184560
- Locations
- 🇰🇷
GachonGill Medical Center, Inchon, Namdong-gu, Korea, Republic of
Study of Fat Malabsorption by Lipiblock Versus Xenical
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 20
- Registration Number
- NCT01170806
- Locations
- 🇧🇷
LIMED (Laboratory of Investigation of Metabolism and Diabetes)/GASTROCENTRO/University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- Albany College of Pharmacy and Health Sciences
- Target Recruit Count
- 19
- Registration Number
- NCT01035333
- Locations
- 🇺🇸
Albany College of Pharmacy and Health Sciences, Albany, New York, United States
Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Yazd Research & Clinical Center for Infertility
- Target Recruit Count
- 80
- Registration Number
- NCT01003483
- Locations
- 🇮🇷
Research and Clinical Center for Infertility, Yazd, Iran, Islamic Republic of
Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 20
- Registration Number
- NCT00991926
Effect of Orlistat in Body Composition
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 131
- Registration Number
- NCT00752726
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇸🇪Sahlgrenska Academy, Goteborg, West Gothland, Sweden
🇺🇸Duke Clinical Research Unit, Durham, North Carolina, United States
Orlistat Treatment of Crigler-Najjar Disease
- Conditions
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2007-04-18
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 16
- Registration Number
- NCT00461799
- Locations
- 🇳🇱
Erasmus University Medical Center, Rotterdam, Netherlands
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 564
- Registration Number
- NCT00422058
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Norwich, United Kingdom
Effectiveness of Brief Counseling for Weight Management
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-03-18
- Target Recruit Count
- 246
- Registration Number
- NCT00212199
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.